Nanoparticles comprising antigens and adjuvants, and immunogenic structures
View Patent ↗Nanoparticles comprising adjuvants and antigens, such as tumor and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.
1. A nanoparticle which comprises:
a core including metal and/or semiconductor atoms; and
a plurality of ligands, each of said plurality being covalently linked to the core,
wherein at least a first ligand of said plurality comprises an antigen which is a pathogen-specific antigen,
and wherein at least a second ligand of said plurality comprises an adjuvant which is a peptide,
and wherein at least a third ligand of said plurality is a carbohydrate-containing ligand, the carbohydrate component of which is a monosaccharide and wherein said third ligand blocks core surface space not occupied by said first and second ligands, thereby controlling the density of said first and second ligands.
2. The nanoparticle of claim 1 , wherein the adjuvant stimulates the innate immune response.
3. The nanoparticle of claim 1 , wherein the adjuvant stimulates a T cell response.
4. The nanoparticle of claim 1 , wherein the peptide activates T helper cells.
5. The nanoparticle of claim 4 , wherein the peptide comprises a protease cleavage site.
6. The nanoparticle of claim 5 , wherein the peptide comprises the amino acid sequence FKLQTMVKLFNRIKNNVA (SEQ ID NO: 1).
7. The nanoparticle of claim 1 , wherein the pathogen is a bacterium, a virus or a parasite.
8. The nanoparticle of claim 1 , wherein at least one of the plurality of ligands is attached to the nanoparticle core via a thiol linker group.
9. The nanoparticle of claim 1 , wherein the core of the nanoparticle comprises a magnetic label.
10. The nanoparticle of claim 9 , wherein the magnetic label is a paramagnetic group comprising Mn +2 , Gd +3 , Eu +2 , cu +2 , V +2 , Co +2 , Ni +2 , Fe +2 , Fe +3 or lanthanides +3 .
11. The nanoparticle of claim 1 , wherein the nanoparticle is water soluble.
12. The nanoparticle of claim 1 , wherein the core of the nanoparticle has a mean diameter between 0.5 and 10 nm.
13. The nanoparticle of claim 1 , wherein the core of the nanoparticle has a mean diameter between 1 and 2.5 nm.
14. The nanoparticle of claim 1 , wherein the nanoparticle including its ligands has a mean diameter between 10 and 30 nm.
15. The nanoparticle of claim 1 , wherein the core is a metallic core.
16. The nanoparticle of claim 15 , wherein the metallic core comprises Au, Ag or Cu.
17. The nanoparticle of claim 15 , wherein the metallic core is an alloy selected from Au/Ag, Au/Cu, Au/Ag/Cu, Au/Pt, Au/Pd, Au/Ag/Cu/Pd, Au/Fe, Au/Cu, Au/Gd, Au/Fe/Cu, Au/Fe/Gd or Au/Fe/Cu/Gd.
18. The nanoparticle of claim 15 , wherein the core of the nanoparticle is magnetic.
19. The nanoparticles of claim 18 , wherein nanoparticle comprises passive metal atoms and magnetic metal atoms in the core in a ratio between about 5:0.1 and about 2:5.
20. The nanoparticle of claim 19 , wherein the passive metal is gold, platinum, silver or copper, and the magnetic metal is iron or cobalt.
21. The nanoparticle of claim 1 , wherein the core comprises semiconductor atoms.
22. The nanoparticle of claim 21 , wherein the core acts as a quantum dot.
23. A composition comprising a population of more than one of the nanoparticles of claim 1 .
24. A composition according to claim 23 further comprising a pharmaceutically acceptable carrier.
25. The nanoparticle of claim 1 , wherein said pathogen-specific antigen is selected from the group consisting of: HIV antigen Man alpha 1-2 Man and parasite antigen Gal alpha 1-3 Gal.
26. The nanoparticle of claim 1 , wherein said monosaccharide is glucose.